160 related articles for article (PubMed ID: 25039318)
1. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance.
van Poppel PC; van Asseldonk EJ; Holst JJ; Vilsbøll T; Netea MG; Tack CJ
Diabetes Obes Metab; 2014 Dec; 16(12):1269-73. PubMed ID: 25039318
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
Larsen CM; Faulenbach M; Vaag A; Vølund A; Ehses JA; Seifert B; Mandrup-Poulsen T; Donath MY
N Engl J Med; 2007 Apr; 356(15):1517-26. PubMed ID: 17429083
[TBL] [Abstract][Full Text] [Related]
3. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
Rissanen A; Howard CP; Botha J; Thuren T;
Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
[TBL] [Abstract][Full Text] [Related]
4. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study.
van Asseldonk EJ; Stienstra R; Koenen TB; Joosten LA; Netea MG; Tack CJ
J Clin Endocrinol Metab; 2011 Jul; 96(7):2119-26. PubMed ID: 21508140
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study.
Hage C; Brismar K; Efendic S; Lundman P; Rydén L; Mellbin L
J Intern Med; 2013 Apr; 273(4):410-21. PubMed ID: 23331339
[TBL] [Abstract][Full Text] [Related]
6. Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.
Hanley AJ; Zinman B; Sheridan P; Yusuf S; Gerstein HC;
Diabetes Care; 2010 Mar; 33(3):608-13. PubMed ID: 20009095
[TBL] [Abstract][Full Text] [Related]
7. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
Utzschneider KM; Tong J; Montgomery B; Udayasankar J; Gerchman F; Marcovina SM; Watson CE; Ligueros-Saylan MA; Foley JE; Holst JJ; Deacon CF; Kahn SE
Diabetes Care; 2008 Jan; 31(1):108-13. PubMed ID: 17909087
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1 receptor antagonist improves normoglycemia and insulin sensitivity in diabetic Goto-Kakizaki-rats.
Akash MS; Rehman K; Sun H; Chen S
Eur J Pharmacol; 2013 Feb; 701(1-3):87-95. PubMed ID: 23348707
[TBL] [Abstract][Full Text] [Related]
9. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.
Larsen CM; Faulenbach M; Vaag A; Ehses JA; Donath MY; Mandrup-Poulsen T
Diabetes Care; 2009 Sep; 32(9):1663-8. PubMed ID: 19542207
[TBL] [Abstract][Full Text] [Related]
10. Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial.
van der Zijl NJ; Moors CC; Goossens GH; Hermans MM; Blaak EE; Diamant M
Diabetes Care; 2011 Apr; 34(4):845-51. PubMed ID: 21330640
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
Moran A; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Greenbaum CJ; Herold KC; Marks JB; Raskin P; Sanda S; Schatz D; Wherrett DK; Wilson DM; Krischer JP; Skyler JS; ; Pickersgill L; de Koning E; Ziegler AG; Böehm B; Badenhoop K; Schloot N; Bak JF; Pozzilli P; Mauricio D; Donath MY; Castaño L; Wägner A; Lervang HH; Perrild H; Mandrup-Poulsen T;
Lancet; 2013 Jun; 381(9881):1905-15. PubMed ID: 23562090
[TBL] [Abstract][Full Text] [Related]
12. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
[TBL] [Abstract][Full Text] [Related]
13. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
[TBL] [Abstract][Full Text] [Related]
14. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
15. Relationship between serum adipsin and the first phase of glucose-stimulated insulin secretion in individuals with different glucose tolerance.
Zhou Q; Ge Q; Ding Y; Qu H; Wei H; Wu R; Yao L; Wei Q; Feng Z; Long J; Deng H
J Diabetes Investig; 2018 Sep; 9(5):1128-1134. PubMed ID: 29432659
[TBL] [Abstract][Full Text] [Related]
16. Muscle-Derived IL-6 Is Not Regulated by IL-1 during Exercise. A Double Blind, Placebo-Controlled, Randomized Crossover Study.
Nordmann TM; Seelig E; Timper K; Cordes M; Coslovsky M; Hanssen H; Schmidt-Trucksäss A; Donath MY
PLoS One; 2015; 10(10):e0139662. PubMed ID: 26448147
[TBL] [Abstract][Full Text] [Related]
17. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance.
Eriksson JG; Lehtovirta M; Ehrnström B; Salmela S; Groop L
J Intern Med; 2006 Jun; 259(6):553-60. PubMed ID: 16704555
[TBL] [Abstract][Full Text] [Related]
18. Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.
de la Peña A; Loghin C; Cui X; Zhang X; Kapitza C; Kelly RP
Diabetes Obes Metab; 2017 Apr; 19(4):517-523. PubMed ID: 27976833
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
Anholm C; Kumarathurai P; Pedersen LR; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
Diabetes Obes Metab; 2017 Jun; 19(6):850-857. PubMed ID: 28124822
[TBL] [Abstract][Full Text] [Related]
20. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
